July 21, 2026 a 08:38 am

RMD: Analysts Ratings - ResMed Inc.

Historical Stock Grades

The most recent analyst ratings for ResMed Inc., dated July 2026, show varied sentiment among the investment community with a leaning towards a cautious outlook. Current ratings reveal only 2 Strong Buy recommendations, 9 Buy, 10 Hold, 1 Sell, and no Strong Sell ratings. Below is a visualization of the current ratings distribution.

Recommendation	Count	Score
Strong Buy	2
Buy	9
Hold	10
Sell	1
Strong Sell	0

Sentiment Development

Over recent months, we have observed a discernible shift in analyst sentiment towards ResMed Inc. While Strong Buy recommendations have slightly decreased, there is a notable increase in Hold ratings, indicative of a more cautious investor stance. The total number of ratings has remained relatively stable, yet the distribution of these ratings suggests analytical prudence.

• Decline in Strong Buy ratings over the months, from 3 to 2.
• Increase in Hold ratings, pointing towards uncertainty or a wait-and-see approach.
• Stable Buy ratings, highlighting potential but moderated enthusiasm.

Percentage Trends

The percentage distribution of analyst ratings over the past months for ResMed Inc. reveals a subtle shift towards neutrality. While Buy ratings have remained consistent, Strong Buy recommendations have depreciated slightly, increasing the proportion of Hold suggestions. This shift may indicate a growing cautiousness in market confidence or acknowledgment of external market pressures.

• From a high in April 2025, Strong Buy ratings have decreased by 50% by July 2026.
• Hold ratings have increased by 42% in the same period.
• Buy recommendations maintained steady, highlighting sector resilience.

The past year's significant change is the transition from a more aggressively bullish to a moderately reserved stance, suggesting analyst caution amid the evolving market landscape.

Latest Analyst Recommendations

The latest updates from analysts show consistent reviews with minimal changes in the majority outlook, though a notable downgrade from Citigroup stands out.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-15	Outperform	Outperform	Mizuho
2026-07-13	Neutral	Buy	Citigroup
2026-07-10	Hold	Hold	Jefferies
2026-07-08	Outperform	Outperform	RBC Capital
2026-07-08	Equal Weight	Equal Weight	Wells Fargo

Analyst Recommendations with Change of Opinion

Critical shifts within analyst opinions have emerged over the past months, especially signified by downgrades which reflect a more conservative outlook on ResMed's potential.

Date	New Recommendation	Last Recommendation	Publisher
2026-07-13	Neutral	Buy	Citigroup
2026-06-17	Equal Weight	Overweight	Morgan Stanley
2025-12-16	Neutral	Outperform	Baird
2025-07-16	Outperform	Sector Perform	RBC Capital
2025-03-05	Buy	Neutral	Citigroup

Interpretation

The shifting analyst sentiment towards ResMed Inc. highlights an evolutionary dynamic within market analysis. The slight trend towards neutrality and increased Hold ratings suggests analysts are exercising caution amid broader economic factors. However, consistent Buy recommendations indicate sustained sector potential and resilience. This balanced outlook suggests that while there is some trepidation, the underlying business fundamentals of ResMed remain strong. The stability of the current consensus rating reflects measured optimism in the company's strategic direction despite a complex macroeconomic environment.

Conclusion

In conclusion, ResMed Inc. continues to maintain its status as a reputable entity within the medical technology sector. Although there has been a subtle shift towards a more cautious analyst outlook, the company's strong industry position fosters confidence. Risk assessments suggest maintaining vigilance regarding market pressures that could impact ResMed's growth trajectory. Nevertheless, the prevailing stable sentiment portrays a predominantly optimistic stance, highlighting resilient operational frameworks as crucial to sustaining future growth and investor sentiment.